Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Sep 5:6:220.
doi: 10.1186/1471-2407-6-220.

CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer

Affiliations

CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer

Dhafir Al-azawi et al. BMC Cancer. .

Abstract

Background: Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer.

Methods: We retrospectively investigated the role of CA 15-3 in conjunction with other clinico-pathological variables as a predictor of response and time to disease recurrence following treatment in LABC. Pre and post primary chemotherapy serum concentrations of CA 15-3 together with other variables were reviewed and related to four outcomes following primary chemotherapy (clinical response, pathological response, time to recurrence and time to progression). Persistently elevated CA 15-3 after PC was considered as consecutively high levels above the cut off point during and after PC.

Results: 73 patients were included in this study. Patients received PC (AC or AC-T regimen) for locally advanced breast cancer. 54 patients underwent surgery. The median follow up was 790 days. Patients with high concentrations of CA 15-3 before PC treatment had a poor clinical (p = 0.013) and pathological (p = 0.044) response. Together with Her-2/neu expression (p = 0.009) and tumour lympho-vascular space invasion (LVI) (p = 0.001), a persistently elevated CA 15-3 post PC (p = 0.007) was an independent predictive factor of recurrence following treatment in LABC.

Conclusion: Elevated CA 15-3 level is predictive of a poor response to chemotherapy. In addition, persistently elevated CA 15-3 levels post chemotherapy in conjunction with lympho-vascular invasion and HER2 status predict a reduced disease free survival following treatment in locally advanced breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meiers survival curve shows that presence of LVI is significantly associated with shorter time to recurrence (p = 0.001 Cox model).
Figure 2
Figure 2
Kaplan-Meiers survival curve, the expression of Her-2/neu receptor was associated with a decrease in disease free time (p = 0.009 Cox model).
Figure 3
Figure 3
Kaplan-Meiers survival curve shows post PC high serum levels of CA15-3 (CA15-3a levels ≤ 30 KU/L, CA15-3b ≥ 30 KU/L) was associated with early disease recurrence (p = 0.007 Cox model).

Similar articles

Cited by

References

    1. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1978;1:53–9. - PubMed
    1. Wolff AC, Davidson NE. Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease. The Oncologist. 2002;7:239–245. doi: 10.1634/theoncologist.7-3-239. - DOI - PubMed
    1. Schwartz G. Neoadjuvant induction chemotherapy. Minerva Ginecol. 2005;57:327–48. - PubMed
    1. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G, Jakesz R. TP53 mutation and p53 over expression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50–6. - PubMed
    1. Ogston KN, Miller ID, Schofield AC, Spyrantis A, Pavlidou E, Sarkar TK, Hutcheon AW, Payne S, Heys SD. Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment? Breast Cancer Res Treat. 2004;86:181–189. doi: 10.1023/B:BREA.0000032986.00879.d7. - DOI - PubMed

Publication types